Sign in

NCT03309150CompletedPhase 1

ATRi Transition Rollover Study

A Rollover Study to Provide Continued Treatment With M6620

Source: ClinicalTrials.gov · Last updated 29 Nov 2024

Brief summary (registry, in English)

The main purpose of the study was to monitor the safety of participant receiving long-term treatment of Berzosertib as monotherapy.

Status (registry)
Completed
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
1 (actual)
First submitted
10 Oct 2017
Start date
10 Jan 2018
Primary completion date
26 Jan 2024
Lead sponsor
Merck KGaA, Darmstadt, Germany
NCT number
NCT03309150
EudraCT number
2017-002354-37

What you commit to

  • Study type: Interventional · Phase 1
  • Participants enrolled: 1
  • From 10 Jan 2018 to the primary completion date, 26 Jan 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Participants experiencing disease progression or unacceptable toxicity at the time of transition into the this study.

Who the study is looking for

  • Participants ongoing treatment in Vertex study VX13-970-002.
  • Participant must be able to understand and provide written informed consent.
  • Participant must be willing and able to comply with the scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive guidelines, and other study procedures.

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Royal Marsden NHS Foundation Trust
Coordinator of this site? Confirm its status		SuttonUnited KingdomUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.